Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IDegAsp · 1 trial · 1 indication
Blood samples were collected at indicated timepoints for analysis of HbA1c. Baseline was defined as the last available pre-dose assessment (on or before Day 1).
| Arm | Type | Description |
|---|---|---|
| iGlarLixi | EXPERIMENTAL | Participants self-administered iGlarLixi (100 units per milliliter \[U/mL\] insulin glargine + 100 or 50 microgram \[mcg\]/mL lixisenatide respectively) subcutaneous (SC) injection once daily on top of metformin +/- sodium-glucose co-transporter 2 inhibitor (SGLT-2i) for 24 weeks. Dose was individually adjusted. |
| IDegAsp | ACTIVE_COMPARATOR | Participants self-administered IDegAsp (100 U/mL of insulin degludec + insulin aspart with a ratio of 70:30) SC injection once daily on top of metformin +/- SGLT-2i for 24 weeks. Dose was individually adjusted. |
| Name | Type | Description |
|---|---|---|
| Insulin glargine/Lixisenatide | DRUG | solution, by subcutaneous injection |
| IDegAsp | DRUG | solution, by subcutaneous injection |
| Metformin | DRUG | Tablet, orally |
| SGLT2 inhibitor | DRUG | Tablet, orally |
Inclusion Criteria: * Participant had at least 18 of age inclusive, at the time of signing the informed consent. * Participants who were diagnosed with T2DM for at least 1 year before the screening visit * Participants who were treated for at least 3 months prior to the screening visit with a stabl...
IDegAsp is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It is currently in Phase 3 clinical development. The drug has been studied in a completed Phase 3 trial involving 582 participants in China, where it was compared against iGlarLixi in patients who had previously been treated with oral antidiabetic drugs.
IDegAsp is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker symbol SNY. Sanofi is conducting clinical trials to evaluate the safety and efficacy of IDegAsp for the treatment of Type 2 Diabetes Mellitus.
IDegAsp is in Phase 3 clinical development for Type 2 Diabetes Mellitus. The drug has completed one Phase 3 trial, which was an active-controlled study. As of the available data, IDegAsp is still investigational and has not been approved by regulatory authorities.
IDegAsp has been studied in one completed Phase 3 clinical trial with the identifier NCT05413369. This trial, titled 'iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)', enrolled 582 participants with Type 2 Diabetes Mellitus in China. The study was active-controlled and included participants aged 18 years and older.
No, IDegAsp is not the same as iGlarLixi. In the clinical trial NCT05413369, iGlarLixi was used as the active comparator against IDegAsp. The trial was designed to compare the two treatments in Chinese participants with Type 2 Diabetes Mellitus who had previously been treated with oral antidiabetic drugs.